Key result
Sodium repletion cuts candesartan AUC by ~26% vs sodium depletion, alongside lower atenolol exposure.
Why the study?
Dietary sodium influences the pharmacodynamic response to renin-angiotensin system blockers and may affect the pharmacokinetics of cardiovascular drugs, but its impact on these drugs is not fully characterized.
Does a sodium repletion diet compared to sodium depletion alter the pharmacokinetics and pharmacodynamics of renin-angiotensin system blockers and atenolol in normotensive males?
RCT (n=64)
randomly assigned
Does a sodium repletion diet compared to sodium depletion alter the pharmacokinetics and pharmacodynamics of renin-angiotensin system blockers and atenolol in normotensive males?
Dietary sodium balance significantly modulates the pharmacokinetics and pharmacodynamics of candesartan and atenolol, highlighting the importance of sodium intake in cardiovascular drug efficacy.
Answers are grounded in this paper and cite their sources.
Sodium intake may alter PK of these agents in healthy volunteers; leaves open relevance to efficacy/safety in hypertensive patients.
Dietary sodium, the main determinant of the pharmacodynamic response to renin-angiotensin system blockade, influences the pharmacokinetics of various cardiovascular drugs. We compared the effect of contrasted sodium diets on the pharmacokinetics of single oral doses of 8 mg candesartan cilexetil, 160 mg valsartan, 10 mg ramipril, and 50 mg atenolol administered to 64 (16 per group) normotensive male subjects randomly assigned to sodium depletion (SD) or sodium repletion (SR) in a crossover study. Pharmacodynamic response was assessed as the increase in plasma renin concentration for renin-angiotensin system blockers and electrocardiographic changes in PR interval duration for atenolol. The area under the curve (AUC) for plasma candesartan and atenolol concentrations was significantly lower for SR than for SD (respective ratios of AUC0-∞: 0.74; [90% CI, 0.66-0.82] and 0.69 [90% CI, 0.54-0.88], respectively), indicating a lack of bioequivalence between SR and SD. SR did not affect the pharmacokinetics of valsartan or ramipril. The increase in plasma renin concentration with the 3 renin-angiotensin system blockers was 10 times lower during the SR than the SD period. In the multiple regression analysis, the AUC0-24 of plasma drug concentration explained <1% and 21% of the variance of the AUC0-24 of delta plasma renin concentration for candesartan (P=0.8882/P=0.0368) during the SR and SD periods, respectively. The atenolol-induced lengthening of PR interval was fully reversed by SR. Thus, sodium balance modulates the pharmacokinetics of candesartan cilexetil and atenolol, with measurable effects on the selected pharmacodynamic end points.
No takes yet. Share an insight, caveat, or question.
Azizi et al. (2013) conducted an RCT in Normotension (n=64). Sodium repletion (SR) vs. Sodium depletion (SD) was evaluated on Area under the curve (AUC) for plasma candesartan and atenolol concentrations (Ratio of AUC0-∞ 0.74 for candesartan and 0.69 for atenolol, 95% CI 0.66-0.82 (candesartan), 0.54-0.88 (atenolol)). Sodium repletion lowered the AUC for candesartan and atenolol compared to sodium depletion in normotensive men.
Synapse has enriched 10 related papers. Consider them for comparative context: